only DSIP (emideltide) was voted down
No direct comparative safety or tolerability data exist for GLP-1 RAs specifically in MC4R -deficient populations, nor are there systematic comparative studies in this group
Wegovy is a once-weekly injection containing the drug semaglutide, approved for weight loss in adults with a BMI over 30, or 27+ with weight-related health issues like high blood pressure or type 2 diabetes
Beyond appetite rebound, abrupt stops may trigger increased cravings for high-calorie, high-sugar foods because your dopamine response to food reward intensifies during the adjustment period
Studies show that its generally well-tolerated and effective for at least four years
At Vive Ageless Weight Loss Center, Rafael Olartecoecheas comprehensive and personalized care ensures the best possible results with oral semaglutide, empowering you to achieve your weight loss goals safely and effectively